Your browser doesn't support javascript.
loading
Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis.
Etta, Indu; Elballushi, Ruaa; Kolesnyk, Viktoriia; Sia, Kim P; Rehman, Sana; Arif, Sehrish; Moonnumackel, Sania J; Nair, Arun.
Afiliación
  • Etta I; Department of Internal Medicine, Kakatiya Medical College, Warangal, IND.
  • Elballushi R; School of Medicine, Royal College of Surgeons in Ireland - Medical University of Bahrain, Muharraq, BHR.
  • Kolesnyk V; First Faculty of Medicine, Charles University, Prague, CZE.
  • Sia KP; School of Medicine, Emilio Aguinaldo College, Manila, PHL.
  • Rehman S; College of Medicine, Fatima Memorial Hospital (FMH) College of Medicine and Dentistry, Lahore, PAK.
  • Arif S; College of Medicine, Fatima Memorial Hospital (FMH) College of Medicine and Dentistry, Lahore, PAK.
  • Moonnumackel SJ; Department of Internal Medicine, Medical City Fort Worth, Fort Worth, USA.
  • Nair A; Department of Pediatrics, Saint Peter's University Hospital, Somerset, USA.
Cureus ; 15(9): e45454, 2023 Sep.
Article en En | MEDLINE | ID: mdl-37859931
Multiple sclerosis (MS) is a chronic autoimmune neurological disorder that significantly impacts the central nervous system (CNS), which includes the brain and spinal cord. Approximately 2.8 million individuals are believed to be living with MS worldwide. The management of MS has evolved considerably over the years, offering a multitude of guidelines, diverse treatment options, and different approaches to signs and symptoms. The present systematic literature review serves as a comprehensive analysis of the current therapeutic options for MS. It provides a thorough literature review of Food and Drug Administration (FDA)-approved drugs comparing their various clinical end points while concurrently assessing their risk-benefit ratio. It also provides an extensive review of current guidelines and offers an in-depth examination of the different approaches to MS. Through this multifaceted approach, this paper facilitates easy access to available treatment options and aims to aid healthcare providers in decision-making as well as providing a foundation for future research aimed at enhancing treatment options for MS.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cureus Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cureus Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos